Navigation Links
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
Date:4/17/2009

SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be held on April 18-22 in Denver, Colorado.

Cylene scientists will unveil the first public description of CX-4945, a first-in-class oral inhibitor of protein kinase CK2. CK2 overexpression is well documented in many cancers and represents a previously unexploited molecular target. CX-4945 is a potent, selective inhibitor of CK2 and modulates key survival pathways in cancer cells. CX-4945, which has broad therapeutic potential in common cancers as well as in niche indications, has advanced rapidly into Phase I clinical trials.

The oral symposium will address the identification of pathway-specific biomarkers, while the posters will address the discovery and characterization of CX-4945 and the ability of CX-4945 to inhibit CK2-driven HIF-1alpha transcription and angiogenesis in hypoxia. In a separate poster, Dr. John Lim will describe the advancement of quarfloxin (CX-3543) into Phase II clinical trials in carcinoid/neuroendocrine tumors. The presentation schedule is:

Sunday, April 19, 2009: 8:00 AM CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the vascular endothelium and suppressing hypoxia-activated HIF-1alpha transcription - Tumor Biology 2, Abstract 145

Tuesday, April 21, 2009: 8:00 AM Quarfloxin phase I clinical data and scientific findings supporting the selection of carcinoid/neuroendocrine tumors as the phase II indication - Clinical Research 12, Abstract 3599

Tuesday, April 21, 2009: 1:00 PM Discovery and characterization of CX-4945 a selective orally bioavailable small molecule inhibitor of pr
'/>"/>

SOURCE Cylene Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
2. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
3. Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
4. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
5. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
6. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
7. NewCardio Leadership to Present Two Abstracts at ISCE Conference
8. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
9. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
10. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
11. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... REYKJAVIK, Iceland, July 1 The ... several new common,single-letter variants in the sequence of the human ... a multinational consortium of scientists,led by a team from deCODE ... 50,000 patients and control participants from fourteen countries.,It is published ...
... announces that it has reached the halfway mark (1,600 patients) ... G auging R esponsiveness with A V erifyNow(R) ... nd S afety). The trial is specifically designed ... for patients who are poor responders to clopidogrel (Plavix(R)). ...
Cached Medicine Technology:deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... Ga. (PRWEB) October 20, 2014 ... and relationship-marketing firm, announced today that William H. ... named the 2014 ISE® Luminary Leadership Award winner. ... the achievements of an outstanding leader and industry ... and contributions in advancing the information security industry. ...
(Date:10/20/2014)... D.C. (PRWEB) October 20, 2014 Zereana Jess-Huff, ... crowned Mrs. Maryland 2014 on a platform to think outside ... scars, and uses her position to raise awareness about women’s ... awareness for breast cancer. You say the color pink and ... I know for a fact that it has not been ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Sit and Slim II . , The ... use Sit and Slim II because it contains Sibutramine ... weight loss product on various websites and possibly in some ... for safety reasons, can significantly increase blood pressure and/or pulse ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
... Recommended back-sleeping could have downside, study suggests, , THURSDAY, ... heads caused by their sleep position have a higher-than-normal ... , The recommendation to place babies on their backs ... syndrome but has increased the number of infants with ...
... , , NEW YORK, Sept. 24 An Ohio woman, ... the baby she,s due to deliver the first week in October is not ... baby boy to his biological parents. The name of the clinic is not ... The AFA is issuing the following statements regarding the matter: , ...
... in Europe may have been caused by excess body weight, ... of cases of new cancers attributable to a body mass ... in central European countries such as the Czech Republic, Latvia, ... study [1], Dr Andrew Renehan, told Europe,s largest cancer congress, ...
... New ... and iPod touch. , ... NC (Vocus) September 24, 2009 -- Modality, Inc. and Elsevier, Inc. today announced two Procedures ... apps help physicians, medical residents and students prepare for, perform and test their knowledge of ...
... ... 4 Top Marketing Mistakes Physicians & Urgent Care Owners Make That Cost Them Plenty of ... The Buzz - All The Latest Cutting Edge, Online Marketing Strategies You,ve Been Hearing About. ... Hickory, NC (PRWEB) September ...
... , ANN ARBOR, Mich., Sept. 24 ... have joined forces today to preserve and protect the highest quality ... protect patient access to cardiac care in whatever Medicare changes or ... Cardiovascular disease is the Number One killer in America, claiming 2,400 ...
Cached Medicine News:Health News:Infant Head-Flattening Linked to Ear Infections 2Health News:The American Fertility Association Responds to Alleged Embryo Mix-Up Case in Ohio 2Health News:The American Fertility Association Responds to Alleged Embryo Mix-Up Case in Ohio 3Health News:Excess body weight causes over 124,000 new cancers a year in Europe 2Health News:Excess body weight causes over 124,000 new cancers a year in Europe 3Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 3Health News:Market Welby Hosting Free Urgent Care and Medical Practice Fast Growth Marketing Webinar Series 2Health News:Cardiologists Mobilize to Protect Quality Cardiac Care for Patients 2Health News:Cardiologists Mobilize to Protect Quality Cardiac Care for Patients 3Health News:Cardiologists Mobilize to Protect Quality Cardiac Care for Patients 4
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively....
... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
... StelKast's Proven Knee System is a long ... proven design. Available in both posterior stabilized ... Proven Knee System provides the flexibility needed ... standardization and ease of identification keeps the ...
... The FluoroNav Virtual ... Surgical Navigation Technologies has ... with exciting technology features ... images and three-dimensional models ...
Medicine Products: